While the blockade of the PD-1/PD-L1/PD-L2 immunoregulatory axis holds promise as an immunotherapeutic approach for rare FMC subtypes, further investigations are needed, particularly examining the interplay between this pathway and the tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.